Serina Therapeutics, Inc.
serinatx.comWhat Do They Do?
Develops polymer-based drug candidates for people with neurological diseases and other conditions, including Parkinson’s disease, and a drug-delivery platform for pharmaceutical partners working on RNA medicines and antibody-drug conjugates.
10-K for FY2025, filed Mar 25, 2026We are a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases…View ↗
Our business is largely focused on the development of a wholly-owned pipeline of POZ-enabled drug candidates for CNS indications, including…View ↗
We believe that our POZ platform delivery technology has potential for use across a broad range of payloads and indications. Among our…View ↗
Seek to create economic and strategic value through POZ LNP licensing and partnerships across multiple RNA-based therapeutic indications;View ↗
Seek to create economic and strategic value for other applications of the POZ platform, including ADCs;View ↗
How Do They Make Money?
Receives government grants to reimburse certain allowable project costs, with grant income counted over the period when those costs are incurred.
10-K for FY2025, filed Mar 25, 2026The Company receives government grants that reimburse the Company for certain allowable costs for funded projects. Grant revenue is…View ↗
$130K
-
10-K for FY2025, filed Mar 25, 2026
$130K ↗
Who Are Their Customers?
Pharmaceutical companies can license the POZ technology or work with Serina through co-development and other partnerships; Serina’s own drug candidates target patients with neurological diseases.
10-K for FY2025, filed Mar 25, 2026 8-K, filed Aug 13, 2026We believe that our POZ platform delivery technology has potential for use across a broad range of payloads and indications. Among our…View ↗
Continue to expand a network of academic and biopharmaceutical collaborations and commercial partnerships to develop and potentially…View ↗
Our business is largely focused on the development of a wholly-owned pipeline of POZ-enabled drug candidates for CNS indications, including…View ↗
Serina’s POZ platform delivery technology has potential for use across a broad range of payloads and indications. Serina intends to advance…View ↗
Do Revenues Turn Into Profits?
No. It lost $19.2M in FY2025.
10-K for FY2025, filed Mar 25, 2026
−$24MView ↗
10-K for FY2025, filed Mar 25, 2026
−$19.2MView ↗
10-K for FY2025, filed Mar 25, 2026
−$18.1MView ↗
How Are They Changing?
Shrinking. Revenue fell 10% in 4 years, from $144K in FY2021 to $130K in FY2025, about 3% a year.
From cell therapies to polymer drug delivery
The earlier report centered on cell-based therapies and regenerative biology for age-related disease; the current report centers on POZ-enabled drug candidates, led by a Parkinson’s program, and polymer delivery applications for partners.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 25, 2026We are a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging and…View ↗
Our proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, allows us to utilize…View ↗
Our product candidates in the discovery stage include two cell-based therapies derived from telomerase-positive PSCs and two product…View ↗
We are a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases…View ↗
Our business is largely focused on the development of a wholly-owned pipeline of POZ-enabled drug candidates for CNS indications, including…View ↗
We believe that our POZ platform delivery technology has potential for use across a broad range of payloads and indications. Among our…View ↗
Loading...
